60 Degrees Pharmaceuticals Inc. Enters New Sales Agreement with H.C. Wainwright & Co

Reuters
Sep 06
<a href="https://laohu8.com/S/SXTPW">60 Degrees</a> Pharmaceuticals Inc. Enters New Sales Agreement with H.C. Wainwright & Co

60 Degrees Pharmaceuticals Inc. has entered into a new At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC as of September 3, 2025. This agreement allows the company to offer and sell shares of its common stock, with a total potential gross sales value of up to $1,397,533, through Wainwright acting as a sales agent or principal. The move follows the termination of a previous similar agreement with Wallachbeth Capital LLC, effective the same day. The sales under the new agreement will be conducted pursuant to the company's shelf registration statement filed with the SEC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-085040), on September 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10